Recent findings in the pathogenesis of post-chlamydial reactive arthritis

Authors: H. Dejmková
Authors‘ workplace: Revmatologický ústav, Praha
Published in: Čes. Revmatol., 16, 2008, No. 3, p. 114-118.
Category: Overview Reports


Reactive arthritis belongs to spondylarthropathies, and mostly has a good prognosis. HLA-B27 positivity and Chlamydia-induced reactive arthritis belong to unfavourable prognostic factors, which incline to a chronic course of the disease. The genetic characteristics of the host as well as the characteristics of Chlamydia are probably implicated in a chronic course of the disease. The article points out some recent findings in the pathogenesis and their significance in the therapy. New therapeutic directions deal mostly with the choice of new, more optimal, antibiotic treatment and the possibilities and difficulties of biological therapy.

Key words:
reactive arthritis, post-chlamydial reactive arthritis, pathogenesis, therapy


1. Colmegna I, Espinoza LR. Recent advances in reactive arthritis. Curr Rheumatol Rep 2005; 7(3): 201–7.

2. Astrauskiene D, Bernotiene E. New insights into bacterial persistence in reactive arthritis. Clin Exp Rheumatol 2007; 25: 470–9.

3. Wollenhaupt J, Zeidler H. Undifferentiated arthritis and reactive arthritis. Curr Opin Rheumatol 1998; 10: 306–313.

4. Sieper J, Fendler C, Laitko S, et al. No benefit of long – term ciprofloxacin treatment in patiens with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double blind , randomized, placebo-controlled study. Arthritis Rheum 1999; 42: 1386–96.

5. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 2003; 62: 880–4.

6. Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rhem Dis 2003; 62: 655–8.

7. Beutler AM, Schumacher HR, Whittum-Hudson, et al. Case report:in situ hybridization for detection of innaparent infection with Chlamydia trachomatis in synovial tissue of patient with Reiter’s syndrome. Am J Med Sci 1995; 310: 206–13.

8. Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, et al. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother 2000; 44: 3288–97.

9. Dejmková H, Mareš Z, Galatíková J, et al. Antibiotická léčba reaktivní artritidy pacientů z Národního registru revmatických chorob. Čes Revmatol 2004; 2: 76–81.

10. Leirisalo-Repo M. Early arthritis and infection. Curr Opin Rheumatol 2005; 17: 433–9.

11. Braun J,Yin Z,Spiller I, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999; 42: 2039–44.

12. Fiorillo MT, Ruckert C, Hulsmeyer M, et al. Allele-dependent similarity between viral and self-peptide presentation by HLA-B27 subtypes. J Biol Chem 2005; 280: 2962–71.

13. Thiel A, Wu P, Lauster R, et al. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum 2000; 43: 2834–2842.

14. Rudwaleit M, Siegert S, Yin Z, et al. Low T cell production of TNF-alpha and IFN-gamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorhism. Ann Rheum Dis 2001; 60: 36–42.

15. Zeidler HK, Schumacher HR. Chlamydia-induced arthritis. In The Spondyloarthritides. Edited by Calin A, Taurog JD. Oxford, New York, Tokyo: Oxford University Press 1998; 69–96.

16. Byrne GI,Schober CS, Willians DM, et al. Characterization of gamma interferon –mediated cytotoxicity to chlamydia –infected fibroblasts. Infect Immun 1989; 57: 870–4.

17. Kotake S, Schumacher HR, Arayssi TK, et al. Gamma interferon and interleukin –10 gene expression in synovial tissues from patients with early stages of chlamydia-associated arthritis and undifferentiated oligoarthritis and from healthy volunteers. Infect Immun 1999; 67: 2682–6.

18. Kim Tae-Hwan, Uhm Wan-Sik, Inman RD. Pathogenesis of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol 2005; 17: 400–5.

19. Jendro MC, Fingerle F, Deutsch T, et al. Chlamydia trachomatis-infected macrophages induce apoptosis of activated T cells by secretion of tumor necrosis factor-alpha in vitro. Med Microbiol Immunol 2004; 193: 45–52.

20. Hess S, Rheinheimer C, Tidow F, et al. Chlamydia trachomatis –induced up-regulation of glycoprotein 130 cytokines, transcription factors and antiapoptotic genes. Arthritis Rheum 2001; 44(10): 2392–2401.

21. Fan T, Lu H, Hu H, et al. Inhibition of apoptosis in chlamydia –infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 1998; 187: 487–96.

22. Meador R, Hsia E, Kitumnuaypong T, et al. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S130-S134.

23. Tuokko J, Koskinen S, Westman P, et al. Tumor necrosis factor microsatellites in reactive arthritis. Br J Rheumatol 1998; 37: 1203–6.

24. Kuipers JG, Zeidler H, Kohler L. How does Chlamydia cause arthritis? Rheum Dis Clin North Am 2003; 29: 613–29.

25. Gérard HC, Branigan PJ, Schumacher HR. Synovial Chlamydia trachomatis in patiens with reactive arthritis /Reiter’s syndrome/ are viable but show aberrant gene expression. J Rheumatol 1998; 25: 734–42.

26. Tomáš T, Pazourek L. Periprotetický infekt-biofilmový aspekt. Ortopedie 2008; 2: 13–18.

27. Chaisson RE. Treatment of chronic infections with rifamycins: is resistance likely to follow? Antimicrob Agents Chemother 2003; 47: 3037–9.

28. Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampicin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. A prospective, radomized 9- month comparison. J Rheumatol 2004; 31(10): 1973–80.

29. Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and othe spondyloarthritides. Expert Opin Incest Druha 2003; 12: 1097–1109.

30. Anandarajah A, Ritchlin TCH. Treatment update on spondylarthropathy. Curr Opin Rheumatol 2005; 17: 247–56.

31. Van den Bosh, Kruithof E, Baeten D, et al. Randomized double-blind comparision of chimeric monoclonal antibody to tumor necrosis factor α (Infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2001; 46: 755–65.

32. Zeidler H,Kuipers J, Köhler L. Chlamydia-induced arthritis. Curr Opin Rheumatol 2004; 16: 380–392.

33. Nanagara R, Li F, Beutler A, et al. Alteration of chlamydia trachomatis biologic behavior in synovial membranes. Arthritis Rheum 1995; 38: 1410–17.

34. Meador RJ, Hsia EC, Kitumnuaypong T, et al. Is etanercept (Enbrel) effective in the treatment of reactive and undifferentiated arthritis? Arthritis Rheum 2001; 44(Suppl): S348(Abst).

35. Brandt J, Haibel H, Reddig J, et al. Successful short term treatment of severe undifferentiated spondylarthropathy with anti-tumor necrosis factor – α monoclonal antibody infliximab. J Rheumatol 2002; 29: 118–22.

36. Brandt J, Khariouzov A, Listing J, et al. Successful short term treatment of patiens with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004; 31(3): 531–8.

37. Gill H, Majithia V. Successful use of infliximabe in the treatment of Reiter’ syndrome: a case report and discussion. Clin Rheumatol 2008; 27(1): 121–3.

Dermatology & STDs Paediatric rheumatology Rheumatology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account